Cas no 2447-57-6 (Sulfadoxine)
Sulfadoxine Chemical and Physical Properties
Names and Identifiers
-
- sulfadoxine
- N1-(5,6-dimethoxypyrimidin-4-yl)sulphanilamide
- Sulphadoxine
- 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
- 4-Sulfanilamido-5,6-dimethoxypyrimidine
- 6-(4-Aminobenzenesulfonamide)-4,5-dimethoxypyrimidine
- 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine
- Fanasil
- Fansidar (suldfadoxine and pyrimethamine)
- Fanzil
- N-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
- N'-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
- Sulforthomidine
- Sulformethoxine
- Sulfadimoxine Fanasil
- Sulfadoxin
- 4-Amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
- SULFADOXINE, USP BP
- 4-amino-N-(4',5'-dimethoxy-6'-pyrimidinyl) benzene sulphonamide
- 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulf
- 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulphonamide
- 6-(4,5-dimethoxy)pyrimidinesulfanilamide
- Sulfadimoxine
- Sulfamethoxine
- Sulformetoxine
- sulphadoxin
- SulphodoxiMe
- Sulfadimoxine , SDM
- Sulphormethoxine
- Sulfadoxinum
- Sulfadoxina
- Solfadossina
- Solfadossina [DCIT]
- Sulfadoxinum [INN-Latin]
- Sulfadoxina [INN-Spanish]
- Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-
- WR 4873
- N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide
- 6-
- SULFADOXINE [INN]
- EN300-118712
- HMS1571K10
- Tox21_110523_1
- Sulfadoxine (JAN/USP/INN)
- NSC759319
- 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide
- 88463U4SM5
- SPBio_003054
- SULFADOXINE [USAN]
- SY045794
- N1-5,6-Dimethoxy-4-pyrimidinylsulfanilamide
- CHEMBL1539
- BSPBio_001168
- DTXCID703608
- KS-5334
- FANSIDAR COMPONENT SULFADOXINE
- BRD-K55250441-001-03-1
- NS00008538
- UNII-88463U4SM5
- D00580
- AKOS015897281
- A817328
- BRN 0625453
- SR-05000001523-1
- 5-25-13-00306 (Beilstein Handbook Reference)
- SULFADOXINE [WHO-IP]
- Sulfadoxine-d3
- 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide;
- GTPL10173
- N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
- SCHEMBL41069
- SULFADOXINE [ORANGE BOOK]
- SR-05000001523-3
- 1173021-35-6
- WR 4073
- NSC 759319
- Sulfadoxine, United States Pharmacopeia (USP) Reference Standard
- Prestwick3_001094
- Sulfadoxin 1000 microg/mL in Acetonitrile
- CAS-2447-57-6
- Fanasulf
- CCG-213610
- SULFADOXINE [MART.]
- Sulfadoxine (Sulphadoxine)
- SULFADOXINE [VANDF]
- HMS2090P07
- AB00514044_07
- AB00514044_08
- Ro-4-4393
- Sanasil: Sulfadoxine: Sulformetoxin
- HMS2230E05
- C07630
- N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
- HMS3715K10
- H10765
- Z1515385080
- SULFADOXINE [USP MONOGRAPH]
- BPBio1_001286
- J21.373J
- Prestwick0_001094
- EINECS 219-504-9
- MLS002154150
- Prestwick2_001094
- CHEBI:9329
- AB00514044
- SULFADOXINE [EP MONOGRAPH]
- SULFADOXINUM [WHO-IP LATIN]
- Sulfadoxine, European Pharmacopoeia (EP) Reference Standard
- SR-05000001523
- W-107313
- HY-B0439
- Prestwick1_001094
- WR-4073
- Ro-44393
- 4-azanyl-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
- FT-0603610
- HMS2098K10
- SULFADOXINE COMPONENT OF FANSIDAR
- Ro 4-4393
- SULFADOXINE [JAN]
- Sulfadoxin, VETRANAL(TM), analytical standard
- HMS2094C19
- Orthosulfin
- NSC-759319
- SULFADOXINE [MI]
- MFCD00792890
- AB00514044-06
- SBI-0206941.P001
- NCGC00016612-01
- DTXSID6023608
- DB01299
- 2447-57-6
- SULFADOXINE [WHO-DD]
- NCGC00016612-05
- Sulfadoxin, >=95% (TLC)
- SULFADOXINE [USP-RS]
- NCGC00016612-04
- Sulfadoxin, certified reference material, TraceCERT(R)
- Q411557
- Pharmakon1600-01506086
- AC-8428
- NCGC00016612-02
- Tox21_110523
- SMR000857259
- BRD-K55250441-001-06-4
- Sulfadoxine [USAN:USP:INN:BAN:JAN]
- s2511
- 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide
- HMS3371I15
- BBL023187
- 1ST4006
- STL356042
- DB-046463
- BRD-K55250441-001-12-2
- BRD-K55250441-001-13-0
- Sulfadoxine
-
- MDL： MFCD00792890
- Inchi： 1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
- InChI Key： PJSFRIWCGOHTNF-UHFFFAOYSA-N
- SMILES： S(C1C=CC(=CC=1)N)(NC1C(=C(N=CN=1)OC)OC)(=O)=O
Computed Properties
- Exact Mass: 310.07400
- Monoisotopic Mass: 310.074
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 21
- Rotatable Bond Count: 5
- Complexity: 420
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 0.7
- Topological Polar Surface Area: 125
Experimental Properties
- Color/Form: White or white crystalline powder
- Density: 1.4006 (rough estimate)
- Melting Point: 196.0 to 200.0 deg-C
- Boiling Point: 522.8°C at 760 mmHg
- Flash Point: 270
- Refractive Index: 1.6270 (estimate)
- Solubility: Soluble in ethanol & ammonium hydroxide (9:1) at 20mg/ml
- PSA: 124.81000
- LogP: 2.61180
- Merck: 8906
Sulfadoxine Security Information
-
Symbol:
- Prompt：warning
- Signal Word：Warning
- Hazard Statement： H315-H319-H335
- Warning Statement： P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：2
- Hazard Category Code： 36/37/38
- Safety Instruction： S26
- RTECS：DA9500000
-
Hazardous Material Identification：
- Toxicity：LD50 in mice (microcrystals, mg/kg): 5200 orally, 2900 s.c., 2900 i.p. (Bhni)
- Storage Condition：2-8°C
- Risk Phrases：R36/37/38
Sulfadoxine Customs Data
- HS CODE：2935009090
- Customs Data：
China Customs Code:
2935009090Overview:
2935009090 Other sulphonates(Acyl)amine. VAT:17.0% Tax refund rate:9.0% Regulatory conditions:nothing MFN tariff:6.5% general tariff:35.0%
Declaration elements:
Product Name, component content, use to
Summary:
2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%
Sulfadoxine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | S818335-100g |
Sulfadoxin |
2447-57-6 | 96% | 100g |
￥1,799.00 | 2022-08-31 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 31736-250MG |
Sulfadoxine |
2447-57-6 | 250mg |
￥522.09 | 2024-12-25 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 74627-100MG |
Sulfadoxine |
2447-57-6 | 100mg |
￥2259.07 | 2023-10-22 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | BP310 |
Sulfadoxine |
2447-57-6 | 100mg |
￥2402.97 | 2023-04-25 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | S1950000 |
Sulfadoxine |
2447-57-6 | European Pharmacopoeia (EP) Reference Standard | ￥2792.52 | 2022-02-23 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 1626500-200MG |
Sulfadoxine |
2447-57-6 | 200mg |
￥3302.56 | 2024-12-26 | ||
| Matrix Scientific | 202199-1g |
4-Amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide |
2447-57-6 | 1g |
$193.00 | 2023-09-06 | ||
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | S0899-25G |
Sulfadoxin |
2447-57-6 | >98.0%(T)(HPLC) | 25g |
￥260.00 | 2024-04-17 | |
| TRC | S699070-100mg |
Sulfadoxine |
2447-57-6 | 100mg |
$ 57.00 | 2023-09-06 | ||
| TRC | S699070-1g |
Sulfadoxine |
2447-57-6 | 1g |
$ 63.00 | 2023-09-06 |
Sulfadoxine Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Sulfadoxine Related Literature
-
Michael D. Green,Dwight L. Mount,G. Daniel Todd Analyst 1995 120 2623
-
Li-Jun Zhou,Qinglong L. Wu,Bei-Bei Zhang,Yong-Gang Zhao,Bi-Ying Zhao Environ. Sci.: Processes Impacts 2016 18 500
-
Li-Jun Zhou,Qinglong L. Wu,Bei-Bei Zhang,Yong-Gang Zhao,Bi-Ying Zhao Environ. Sci.: Processes Impacts 2016 18 500
-
Przemys?aw Biegański,?ukasz Szczupak,Manuel Arruebo,Konrad Kowalski RSC Chem. Biol. 2021 2 368
-
Akinranti S. Ajibola,Selina Tisler,Christian Zwiener Anal. Methods 2020 12 576
Related Categories
- Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aminobenzenesulfonamides
- Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides Aminobenzenesulfonamides
- Pesticide Chemicals Pesticide Active Ingredients Standard Substances
- Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances
- Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
Additional information on Sulfadoxine
Introduction to Sulfadoxine (CAS No: 2447-57-6)
Sulfadoxine, a synthetic sulfonamide antibiotic, is widely recognized for its significant role in the field of pharmaceutical chemistry and medicine. With the chemical formula C12H11N2O4S and a molecular weight of 278.32 g/mol, this compound is characterized by its distinct structural and functional properties. The CAS number 2447-57-6 uniquely identifies Sulfadoxine in the global chemical registry, ensuring precise classification and reference in scientific literature and industrial applications.
The pharmacological profile of Sulfadoxine has been extensively studied, particularly in the context of its antimicrobial activity. As a sulfonamide derivative, it exerts its effects by inhibiting bacterial dihydropteroate synthase, a crucial enzyme in the synthesis of folic acid in microorganisms. This mechanism of action makes Sulfadoxine particularly effective against a range of Gram-positive and Gram-negative bacteria, as well as certain protozoal infections. Its historical significance in treating diseases such as malaria and bacterial infections underscores its enduring relevance in modern medicine.
In recent years, researchers have been exploring novel applications and combinations of Sulfadoxine with other therapeutic agents. One notable area of investigation involves its use in combination therapies to enhance efficacy and reduce the risk of resistance development. For instance, studies have demonstrated promising results when Sulfadoxine is paired with antimalarial drugs like artesunate, particularly in regions where drug resistance is prevalent. This synergistic approach not only improves treatment outcomes but also contributes to the global effort to combat infectious diseases effectively.
The chemical stability and solubility characteristics of Sulfadoxine are also subjects of ongoing research. Investigations into its formulation as a prodrug or nanocarrier system have shown potential in improving bioavailability and therapeutic delivery. These advancements are particularly relevant in developing countries where access to medications can be limited due to storage and distribution challenges. By optimizing the pharmacokinetic properties of Sulfadoxine, researchers aim to enhance its accessibility and effectiveness in diverse clinical settings.
Ethical considerations and patient safety are paramount when evaluating the use of Sulfadoxine. While it has demonstrated significant therapeutic benefits, potential side effects such as allergic reactions and hematological disorders must be carefully monitored. Clinical trials have provided valuable insights into the safe dosage regimens and patient populations most likely to benefit from Sulfadoxine therapy. These findings are crucial for healthcare professionals in making informed decisions regarding patient care.
The environmental impact of pharmaceutical compounds like Sulfadoxine is another critical aspect that has garnered attention from researchers. Efforts to minimize environmental contamination through proper disposal and waste management practices are essential for sustainable healthcare practices. Additionally, exploring biodegradable or environmentally friendly formulations of Sulfadoxine could help mitigate ecological risks associated with pharmaceutical waste.
The future directions for Sulfadoxine research are multifaceted, encompassing both traditional pharmacological studies and innovative approaches such as computational modeling and artificial intelligence-driven drug discovery. These technologies hold promise for identifying new therapeutic applications and optimizing existing treatments. By leveraging cutting-edge research methodologies, scientists can unlock the full potential of Sulfadoxine while addressing emerging challenges in global health.
In conclusion, Sulfadoxine (CAS No: 2447-57-6) remains a vital compound in the realm of pharmaceutical chemistry and medicine. Its historical significance, combined with ongoing research efforts, highlights its enduring relevance in addressing infectious diseases worldwide. As scientific understanding continues to evolve, new applications and improvements for Sulfadoxine are likely to emerge, further solidifying its role as a cornerstone in modern therapeutics.
2447-57-6 (Sulfadoxine) Related Products
- 38006-08-5(Sulfamonomethoxine sodium)
- 122-11-2(Sulfadimethoxine)
- 150725-87-4(Ro 46-2005)
- 16461-27-1(Benzenesulfonamide,4-amino-N-(2-ethyl-5,6-dimethoxy-4-pyrimidinyl)-)
- 1037-50-9(Sulfadimethoxine sodium)
- 5018-54-2(N4-Acetyl Sulfadoxine)
- 1173021-35-6(4-Amino-N-[5,6-bis(trideuteriomethoxy)pyrimidin-4-yl]benzenesulfonamide)
- 73068-02-7(Sulfadimethoxine-d6)
- 1220-83-3(Sulfamonomethoxine)
- 39295-60-8(Sulfadoxine mixture with trimethoprim)
